{
    "info": {
        "nct_id": "NCT00050349",
        "official_title": "EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors",
        "criteria": "Inclusion Criteria:\n\n* Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy\n* The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin \\<1.5 X ULN; AST, ALT\\<2.5X ULN (\\<5 X ULN if liver metastases are present)\n* Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry\n* Must have a life expectancy of greater than three (3) months\n* Karnofsky Performance Status \\> 60\n* Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)\n\nExclusion Criteria:\n\n* Patients with symptomatic CNS metastases or leptomeningeal involvement\n* Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.\n* Patients with bone metastases as the only site(s) of measurable disease\n* Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)\n* Patients who have been previously treated with radioactive directed therapies\n* Patients who have been previously treated with epothilone\n* Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\n* Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports\n* Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ\n* Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae\n* Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits\n* HIV+ patients\n* Pregnant or lactating females."
    },
    "atomic_criteria": [
        {
            "raw_text": "biopsy-proven metastatic carcinoid tumors",
            "paraphrased_text": "Patients must have metastatic carcinoid tumors confirmed by biopsy."
        },
        {
            "raw_text": "other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)",
            "paraphrased_text": "Patients may have other neuroendocrine tumors such as Islet cell tumors, Gastrinomas, or VIPomas."
        },
        {
            "raw_text": "at least one measurable lesion (other than bone)",
            "paraphrased_text": "Patients must have at least one measurable lesion that is not in the bone."
        },
        {
            "raw_text": "that has either not been previously irradiated",
            "paraphrased_text": "The measurable lesion must not have been previously irradiated."
        },
        {
            "raw_text": "if previously irradiated has demonstrated progression since the radiation therapy",
            "paraphrased_text": "If the measurable lesion was previously irradiated, it must have shown progression since the radiation therapy."
        },
        {
            "raw_text": "Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry",
            "paraphrased_text": "Patients taking Sandostatin Lar must have been on a stable dose for at least 30 days before entering the study."
        },
        {
            "raw_text": "short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry",
            "paraphrased_text": "Patients on short acting somatostatin analogues must be assessed by the investigator to be on a clinically stable dose before entering the study."
        },
        {
            "raw_text": "Must have a life expectancy of greater than three (3) months",
            "paraphrased_text": "The participant must have a life expectancy of more than three months."
        },
        {
            "raw_text": "Patients with symptomatic CNS metastases",
            "paraphrased_text": "Patients who have symptomatic metastases in the central nervous system."
        },
        {
            "raw_text": "leptomeningeal involvement",
            "paraphrased_text": "Patients who have involvement of the leptomeninges."
        },
        {
            "raw_text": "Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start.",
            "paraphrased_text": "Patients with known brain metastases are eligible only if the metastases have been treated or have been stable for at least six months before the study begins."
        },
        {
            "raw_text": "Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.",
            "paraphrased_text": "Subjects who have had brain metastases in the past must undergo a head CT with contrast to show either response or progression."
        },
        {
            "raw_text": "Patients with bone metastases as the only site(s) of measurable disease",
            "paraphrased_text": "The patient must have bone metastases as the sole location of measurable disease."
        },
        {
            "raw_text": "Patients with hepatic artery chemoembolization within the last 6 months",
            "paraphrased_text": "Patients who have undergone hepatic artery chemoembolization in the past 6 months."
        },
        {
            "raw_text": "one month if there are other sites of measurable disease",
            "paraphrased_text": "Patients who have undergone hepatic artery chemoembolization in the past month if there are other sites of measurable disease."
        },
        {
            "raw_text": "Patients who have been previously treated with radioactive directed therapies",
            "paraphrased_text": "Patients who have received treatments involving radioactive directed therapies in the past."
        },
        {
            "raw_text": "Patients who have been previously treated with epothilone",
            "paraphrased_text": "Patients must have received prior treatment with epothilone."
        },
        {
            "raw_text": "Patients with any peripheral neuropathy",
            "paraphrased_text": "Patients must not have any peripheral neuropathy."
        },
        {
            "raw_text": "unresolved diarrhea greater than Grade 1",
            "paraphrased_text": "Patients must not have unresolved diarrhea that is greater than Grade 1."
        },
        {
            "raw_text": "Patients with severe cardiac insufficiency",
            "paraphrased_text": "Individuals who have severe cardiac insufficiency."
        },
        {
            "raw_text": "patients taking Coumadin or other warfarin-containing agents",
            "paraphrased_text": "Individuals who are taking Coumadin or other medications that contain warfarin."
        },
        {
            "raw_text": "with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports",
            "paraphrased_text": "Except for those taking low dose warfarin (1 mg or less) for maintaining in-dwelling lines or ports."
        },
        {
            "raw_text": "Patients with active or suspected acute or chronic uncontrolled infection",
            "paraphrased_text": "Patients must not have an active or suspected acute or chronic uncontrolled infection."
        },
        {
            "raw_text": "including abcesses or fistulae",
            "paraphrased_text": "Patients must not have abscesses or fistulae."
        },
        {
            "raw_text": "Patients with a medical or psychiatric illness that would preclude study or informed consent",
            "paraphrased_text": "Patients who have a medical or psychiatric condition that prevents them from participating in the study or giving informed consent."
        },
        {
            "raw_text": "history of noncompliance to medical regimens",
            "paraphrased_text": "Patients who have a history of not following medical treatment plans."
        },
        {
            "raw_text": "inability or unwillingness to return for all scheduled visits",
            "paraphrased_text": "Patients who are unable or unwilling to attend all scheduled study visits."
        },
        {
            "raw_text": "HIV+ patients",
            "paraphrased_text": "Patients who are HIV positive"
        },
        {
            "raw_text": "Pregnant or lactating females",
            "paraphrased_text": "Females who are pregnant or breastfeeding are not eligible."
        }
    ],
    "leftovers": [
        "Inclusion Criteria:",
        "* Patients with ",
        " or ",
        " with ",
        " ",
        " or ",
        "* ",
        " and ",
        "* ",
        "Exclusion Criteria:",
        "* ",
        " or ",
        "* ",
        " ",
        "* ",
        "* ",
        " (",
        ")",
        "* ",
        "* ",
        "* ",
        " or ",
        "* ",
        " ",
        " ",
        "* ",
        " ",
        "* ",
        " and/or ",
        " or ",
        "* ",
        "* ",
        "."
    ]
}